"The two notices of allowance strengthen our U.S. patent estate for NGX-1998," said Ronald Martell, president and CEO of NeurogesX. "Our Phase 2 data suggest that NGX-1998's product profile, including a five-minute application for up to three months of pain relief, make it an exciting advance in pain therapy. We are continuing our efforts to move into Phase 3 clinical trials as expeditiously as possible."
Related Articles on Pain Management:Dr. Scott Glaser: 3 Concept in Interventional Pain Management to Reduce Hospitalization
Evolving Clinical Developments in Interventional Pain Management: The Mild Procedure
Nebraska Physician Group Opens Neuroscience Pain Clinic